Q1 2025 Earnings Call Transcript May 13, 2025 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

In Europe, the drug's use is restricted to those who have one or no copies of the ApoE4 gene and who have amyloid beta plaques in their ... 2024 revenue of 3.56 billion yuan ($490 million).

These brain changes include the accumulation of beta-amyloid and tau proteins. ARUP validated the pTau 217 test using carefully characterized samples from Eli Lilly and Company's Phase 3 ...

View the Post & Courier for Sunday, May 4, 2025 ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

Live human brain slices show that only a razor‑thin balance of amyloid beta keeps synapses safe. Any disruption, even slight, ...

Scientists at Northwestern University have developed a new approach that directly combats the progression of ...

Individuals who were told they didn’t have elevated amyloid beta had reductions in all emotional parameters assessed compared to baseline, while peers who were told they did have amyloid beta ...